Cefazolin Sodium for Injection
Function and Efficacy
After intramuscular injection of 500 mg of this product, the peak blood concentration (Cmax) reaches 38 mg/L (32-42 mg/L) after 1-2 hours, and the blood concentration can still be measured at 7 mg/L after 6 hours. 0.5 g of this product is intravenously dripped within 20 minutes, and the peak blood concentration is 118 mg/L, and the effective concentration is maintained for 8 hours. This product is difficult to penetrate the blood-cerebrospinal fluid barrier, and the drug concentration cannot be measured in the cerebrospinal fluid. Cefazolin can reach a higher concentration in pleural effusion, ascites, pericardial fluid and synovial fluid. The drug concentration in inflammatory exudate is basically equal to the serum concentration; the concentration in bile is equal to or slightly exceeds the blood concentration in the same period. The fetal blood concentration is 70% to 90% of the maternal blood concentration, and the content in breast milk is low. The protein binding rate of this product is 74% to 86%. The blood elimination half-life (t1/2β) of normal adults is 1.5 to 2 hours, which can be extended to 2.5 hours in the elderly. The t1/2β of patients with renal failure can be prolonged, and the endogenous creatinine clearance rate is 12 hours and 57 hours when it is 12-17ml/min and less than 5ml/min, respectively. The t1/2β of newborns within 1 week after birth is 4.5-5 hours. This product is not metabolized in the body; the original drug is filtered through the glomerulus, and part of it is secreted in the urine through the renal tubules. 80%-90% of the dose can be excreted within 24 hours. Probenecid can increase the blood drug concentration by about 30% and prolong the effective blood drug concentration time. The blood drug concentration decreases by 40%-50% after 6 hours of hemodialysis; peritoneal dialysis generally cannot remove this product.
Ingredients
Cefazolin Sodium
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Cefazolin sodium saltIngredients |
After intramuscular injection of 500 mg of this product, the peak blood concentration (Cmax) reaches 38 mg/L (32-42 mg/L) after 1-2 hours, and the blood concentration can still be measured at 7 mg/L after 6 hours. 0.5 g of this product is intravenously dripped within 20 minutes, and the peak blood concentration is 118 mg/L, and the effective concentration is maintained for 8 hours. This product is difficult to penetrate the blood-cerebrospinal fluid barrier, and the drug concentration cannot be measured in the cerebrospinal fluid. Cefazolin can reach a higher concentration in pleural effusion, ascites, pericardial fluid and synovial fluid. The drug concentration in inflammatory exudate is basically equal to the serum concentration; the concentration in bile is equal to or slightly exceeds the blood concentration in the same period. The fetal blood concentration is 70% to 90% of the maternal blood concentration, and the content in breast milk is low. The protein binding rate of this product is 74% to 86%. The blood elimination half-life (t1/2β) of normal adults is 1.5 to 2 hours, which can be extended to 2.5 hours in the elderly. The t1/2β of patients with renal failure can be prolonged, and the endogenous creatinine clearance rate is 12 hours and 57 hours when it is 12-17ml/min and less than 5ml/min, respectively. The t1/2β of newborns within 1 week after birth is 4.5-5 hours. This product is not metabolized in the body; the prototype drug is filtered through the glomerulus, and part of it is secreted in the urine through the renal tubules. 80% to 90% of the administered dose can be excreted within 24 hours. Probenecid can increase the blood drug concentration by about 30% and prolong the effective blood drug concentration time. The blood drug concentration decreases by 40% to 50% after 6 hours of hemodialysis; peritoneal dialysis generally cannot clear this product. More |
27164-46-1 | 30 |
Appearance
This product is white or off-white powder or crystalline powder; odorless.
Indication
It is suitable for the treatment of respiratory tract infections such as otitis media, bronchitis, pneumonia, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, hepatobiliary system infections, and eye, ear, nose, and throat infections caused by sensitive bacteria. This product can also be used as a preventive drug before surgery. This product is not suitable for central nervous system infections. The efficacy is poor for chronic urinary tract infections, especially those with urinary tract anatomical abnormalities. This product is not suitable for the treatment of gonorrhea and syphilis.
Usage and Dosage
Common adult dose: slow intravenous push, intravenous drip or intramuscular injection, 0.5-1g at a time, 2-4 times a day. In severe infections, the dose can be increased to 6g a day, administered intravenously in 2-4 times. Common child dose: 50-100mg/kg a day, slow intravenous push, intravenous drip or intramuscular injection in 2-3 times. When the creatinine clearance of patients with renal impairment is greater than 50ml/min, the drug can still be administered at a normal dose. When the creatinine clearance is 20-50ml/min, 0.5g every 8 hours; when the creatinine clearance is 11-34ml/min, 0.25g every 12 hours; when the creatinine clearance is less than 10ml/min, 0.25g every 18-24 hours. The first dose for all patients with varying degrees of renal impairment is 0.5g. When children with impaired renal function are given cefazolin, first give 12.5 mg/kg, followed by maintenance doses. When the creatinine clearance is above 70 ml/min, normal doses can still be given; when the creatinine clearance is 40-70 ml/min, 12.5-30 mg/kg of body weight should be given every 12 hours; when the creatinine clearance is 20-40 ml/min, 3.1-12.5 mg/kg of body weight should be given every 12 hours; when the creatinine clearance is 5-20 ml/min, 2.5-10 mg/kg of body weight should be given every 24 hours.
Adverse Reactions
1. The incidence of thrombophlebitis and pain in the intramuscular injection area after intravenous injection is less and milder than that of cephalothin. 2. The incidence of drug rash is 1.1%, the incidence of eosinophilia is 1.7%, and drug fever occasionally occurs. 3. Some patients may experience temporary elevation of serum aminotransferase and alkaline phosphatase. 4. Patients with renal impairment may experience encephalopathy when using high doses (12g per day) of this product. 5. Superinfection with Candida albicans is occasionally seen.
Precautions
This product is contraindicated in patients who are allergic to cephalosporins or have a history of anaphylactic shock or immediate reaction to penicillin.
Special Population Medication
Precautions for children: This product is not recommended for premature infants and newborns under 1 month old. Precautions for pregnancy and lactation: This product has a low content in breast milk. However, breastfeeding women should still suspend breastfeeding when taking the drug. Precautions for the elderly: The T1/2beta of this product in the elderly is significantly longer than that in young people. The dosage should be appropriately reduced or the dosing interval should be extended according to renal function.
Drug Interactions
1. This product is contraindicated with the following drugs and cannot be infused in the same bottle: amikacin sulfate, kanamycin sulfate, chlortetracycline hydrochloride, oxytetracycline hydrochloride, tetracycline hydrochloride, erythromycin gluconate, polymyxin B sulfate, sodium colistin methanesulfonate, pentobarbital, calcium glucoheptonate, calcium gluconate. 2. This product can enhance the antibacterial effect in vitro when used in combination with gentamicin or amikacin. 3. This product may increase nephrotoxicity when used in combination with strong diuretics, and may increase the nephrotoxicity of the latter when used in combination with aminoglycoside antibiotics. 4. Probenecid can increase the blood concentration of this product and prolong its blood half-life.
Storage
Sealed, store in a cool, dark (avoid light and not exceeding 20°C) dry place.
Packaging Specification
2.0g based on C14H14N8O4S3
Manufacturer
Zhuhai United Pharmaceutical Co., Ltd. Zhongshan Branch
-
Founded in:
1997-07-28 -
Address:
No. 12, Jialian Road, Tanzhou Town, Zhongshan City, Guangdong Province -
Tax NO.:
91442000X180811958 -
Registered Funds:
- -
Website:
-
Email: